TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7751822
Drug: lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/day)
Study: 7751822
Drug: lovastatin +
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lovastatin + high cholesterol diet (mean 1071 mg/day)
Study: 27025903
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus S-1 therapy
Study: 18930988
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with methotrexate (MTX) plus infliximab (IFX)
Study: 18930988
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with methotrexate (MTX) plus infliximab (IFX)
Study: 17444858
Drug: fermented papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: fermented papaya preparation (FPP) 9 g/day
Study: 10221185
Drug: Oral Diantalvic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Diantalvic (paracetamol-noramidopyrine) as rescue analgesic
Study: 6812750
Drug: Ketanserin 10
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 10 mg intravenously
Study: 30348514
Drug: ALKS 3831
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALKS 3831 10/10 (10‐mg olanzapine/10‐mg samidorphan)
Study: 30348514
Drug: ALKS 3831
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALKS 3831 20/10 (20‐mg olanzapine/10‐mg samidorphan)
Study: 20424282
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy; specific dosage and duration not mentioned.
Study: 20424282
Drug: No treatment;
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment; control group not explicitly mentioned.
Study: 18791892
Drug: Traditional weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Traditional weekly sessions (TWS)
Study: 8807168
Drug: Propofol (RivP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (RivP 18, 15, 12, 9 and 0 mg.kg‐1.hr‐1)
Study: 6368345
Drug: Propranolol (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (16 mg)
Study: 6368345
Drug: Penbutolol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (4 mg)
Study: 31272502
Drug: Nitrous oxide/oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrous oxide/oxygen mixture (1:1) plus conventional treatment (no analgesics)
Study: 31272502
Drug: Oxygen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen plus conventional treatment (no analgesics)
Study: 22863266
Drug: albIFN 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: albIFN 1200 μg q4wk
Study: 22863266
Drug: albIFN 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: albIFN 1500 μg q4wk
Study: 8682015
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg alteplase (n = 246)
Study: 29741634
Drug: peginterferon alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2a in combination with lamivudine
Study: 16323175
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy
Study: 21080348
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) cyclophosphamide (CYC)
Study: 12236626
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg, days 1-7; 40 mg, days 8-14)
Study: 7478022
Drug: Direct intraventricular
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct intraventricular infusion of urokinase
Study: 18304172
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus ointment 0.03% vs 0.1%
Study: 12874940
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (1 hour, twice a week)
Study: 8739172
Drug: Guided tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided tissue regeneration (GTR) with non-resorbable ePTFE membranes and systemic antimicrobial therapy (ornidazole)
Study: 8739172
Drug: No membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: No membrane and systemic antimicrobial therapy (ornidazole)
Study: 24847853
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g protein · kg body weight(‐1) · d(‐1), 7% of energy from protein)
Study: 22863669
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg) in subjects with mild renal impairment (50 to ≤ 80 mL/min)
Study: 2095605
Drug: Ambroxol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (1 g/day for 4 days before and 4 days after surgery)
Study: 31734103
Drug: Cenobamate 100
Normalized name: cenobamate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 100 mg
Study: 31292226
Drug: Cenobamate 250
Normalized name: cenobamate 250 mg/day (200 mg x 1 and 50 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 250 mg
Study: 31734103
Drug: Cenobamate 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate 400 mg
Study: 31292226
Drug: Cenobamate (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenobamate (250 mg and 400 mg doses)
Study: 23564348
Drug: 300,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300,000 IU (7,500 μg) i.m. cholecalciferol
Study: 21214633
Drug: Topical combination
Normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical combination of levomenol and heparin (Group A)
Study: 16254422
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (Group C)
Study: 21214633
Drug: Cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream base with no active substances (Group D)
Study: 17954367
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with olmesartan 10 mg/day and temocapril 2 mg/day
Study: 17954367
Drug: Temocapril 2
Normalized name: temocapril
DrugBank: Temocapril (DB08836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocapril 2 mg/day
Study: 11745583
Drug: Directed problem-solving
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directed problem-solving treatment program (control)
Study: 2520494
Drug: PGE1 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE1 (200 micrograms 4 times daily)
Study: 12457302
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg, 300 mg, or 500 mg administered as a single dose or daily for 10 consecutive days
Study: 30788810
Drug: GIK (glucose-insulin-potassium)
Normalized name: glucose / potassium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (glucose-insulin-potassium)
Study: 7030855
Drug: GIK +
Normalized name: Glucose-Insulin-Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK + Verapamil (50 mg continuous drip)
Study: 7030855
Drug: GIK +
Normalized name: Glucose-Insulin-Potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK + Digoxin (0.25 mg b.i.d.)
Study: 26884592
Drug: 50.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.4 Gy in 28 fractions combined with two 5‐day cycles of bolus 5‐Fu 325 mg/m(2)/day and leucovorin 20 mg/m(2)/day during the first and fifth week of irradiation along with five infusions of oxaliplatin 50 mg/m(2) once weekly (group B)
Study: 20860447
Drug: Intraoperative wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative wound infiltration with 150 mL ropivacaine (2 mg/mL), 1 mL ketorolac (30 mg/mL), and 0.5 mL epinephrine (1 mg/mL) combined with intraarticular infusion (4 mL/h) of 190 mL ropivacaine (2 mg/mL) plus 2 mL ketorolac (30 mg/mL) (group A)
Study: 20860447
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion (4 mL/h) of 192 mL ropivacaine (2 mg/mL) combined with 6 intravenous administrations of 0.5 mL ketorolac (30 mg/mL) for 48 h postoperatively (group E)
Study: 10529932
Drug: 2.0% dorzolamide/0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0% dorzolamide/0.5% timolol fixed combination (COSOPT)
Study: 9700984
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg/day)
Study: 21093861
Drug: Elevated serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated serum PAPP‐A (≥4mIU/L)
Study: 21934637
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sildenafil
Study: 10082152
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral glibenclamide
Study: 1778860
Drug: Erythromycin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (200 mg daily for neonates, 1000 mg daily for adults)
Study: 1778860
Drug: Roxithromycin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (50 mg daily for neonates, 300 mg daily for adults)
Study: 29095417
Drug: Web-based multimedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based multimedia patient engagement program (Emmi Solutions)
Study: 8208677
Drug: GenHevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: GenHevac B vaccine (20 micrograms)
Study: 8208677
Drug: Hevac B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hevac B vaccine (5 micrograms)
Study: 4875006
Drug: Neomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (2 g orally daily)
Study: 30698725
Drug: Milk protein
Normalized name: Milk protein
DrugBank: Casein (DB10516)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein (MILK) 20 g
Study: 30698725
Drug: Micellar casein
Normalized name: Douxo Micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micellar casein protein (CASEIN) 20 g
Study: 29349988
Drug: Patient-Controlled Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Intravenous Analgesia (PCIA) with controlled instillation of sufentanil
Study: 29349988
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia including continuous femoral nerve block, local injection of knee joint, and buprenorphine patches
Study: 26479485
Drug: Manual-based multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual-based multimodal treatment (MT)
Study: 9221571
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (group A)
Study: 9221571
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin (group B)
Study: 29723235
Drug: Anma therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anma therapy (AMT)
Study: 29723235
Drug: No Anma
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Anma therapy (no-AMT)
Study: 21786434
Drug: Cilostazol pretreatment
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol pretreatment (200 mg/day for 7 days)
Study: 19368659
Drug: MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI after ingestion of 200 mL meal
Study: 19368659
Drug: MRI after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI after ingestion of 800 mL meal
Study: 19368659
Drug: Breath test
Normalized name: MERETEK UBT BREATH TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath test (BT) after ingestion of 200 mL meal
Study: 19368659
Drug: Breath test
Normalized name: MERETEK UBT BREATH TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breath test (BT) after ingestion of 800 mL meal
Study: 17077429
Drug: Individual music
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual music therapy plus standard care
Study: 9065193
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of 0.4% chlorhexidine
Study: 9065193
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of sterile water (placebo)
Study: 29277353
Drug: PHiD-CV 4-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV 4-dose vial (with preservative)
Study: 27681760
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation therapy (PMRT)
Study: 18356694
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus tirofiban infusion administered together during inclusion (n = 10)
Study: 18356694
Drug: Clopidogrel administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administered at inclusion and followed 2 hours after by tirofiban (n = 7)
Study: 18356694
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus tirofiban infusion (group A)
Study: 18356694
Drug: Clopidogrel administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administered at inclusion and followed 2 hours after by tirofiban (group B)
Study: 15978308
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment A): intact tablet with 120 mL water
Study: 15978308
Drug: Treatment B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: crushed tablet mixed with 4 oz applesauce
Study: 15978308
Drug: Treatment C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: crushed tablet mixed with 120 mL of a common ENF
Study: 14613023
Drug: Anastrozole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anastrozole (1 mg once daily)
Study: 14613023
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Anastrozole plus Tamoxifen
Study: 10356087
Drug: 500-microgram phylloquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500-microgram phylloquinone tablet
Study: 10356087
Drug: 150 g
Normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 g of raw spinach
Study: 10356087
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of spinach
Study: 8403654
Drug: Debridement and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement and intravenous antibiotics for four weeks
Study: 8403654
Drug: Debridement, gentamicin-polymethylmethacrylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debridement, gentamicin-polymethylmethacrylate (Septopal) beads, and perioperative broad-spectrum parenteral antibiotics
Study: 24607303
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (20 g)
Study: 24607303
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (50 g)
Study: 24607303
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (5 g)
Study: 16914701
Drug: Daptomycin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (6 mg/kg daily)
Study: 6396248
Drug: 10% crotamiton
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% crotamiton lotion
Study: 26685701
Drug: Vilazodone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilazodone (up to 40 mg/day)
Study: 24628408
Drug: Face Mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face Mask (FM) treatment
Study: 24628408
Drug: Face Mask
Normalized name: CVS Face Masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face Mask (FM) treatment with Rapid Maxillary Expansion (RME)
Study: 21179724
Drug: Chinese drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese drugs for benefiting‐qi, activating‐blood, dissolving phlegm and removing‐toxin (CDs) combined with basic therapy
Study: 24261227
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy only (Control)
Study: 15620437
Drug: Orlistat 360
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 360 mg/day for one year
Study: 10347106
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment
Study: 2297261
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue spray (2 ml applied before thoracotomy closure)
Study: 832923
Drug: Hypnotic subjects
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic subjects (Ss)
Study: 832923
Drug: Hypnotic Ss
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotic Ss responding to difficult task aspects
Study: 31488259
Drug: Steroids (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (first line treatment)
Study: 31488259
Drug: Rituximab (monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (monotherapy or in association with steroids)
Study: 31488259
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of steroids with rituximab
Study: 25730283
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection plus soft coagulation using hemostatic forceps (HFSC)
Study: 25730283
Drug: Epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine injection plus argon plasma coagulation (APC)
Study: 23523332
Drug: Injections during
Normalized name: Pro-C-Dure 6 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections during labor
Study: 17084960
Drug: alpha‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐blocker
Study: 17084960
Drug: triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: triple therapy (alpha‐blocker, anti‐inflammatory, and muscle relaxant)
Study: 12118903
Drug: Darusentan 10
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 10 mg
Study: 15276394
Drug: Darusentan 25
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 25 mg
Study: 19748665
Drug: Darusentan 50
Normalized name: Darusentan
DrugBank: Darusentan (DB04883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darusentan 50 mg
Study: 26412349
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy alone without chemotherapy (for recurrence score of 0 to 10)
Study: 23679351
Drug: Motesanib 125
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 125 mg once daily (Arm A)
Study: 23679351
Drug: Motesanib 75
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 75 mg twice daily, 14-days-on/7-days-off (Arm B)
Study: 23679351
Drug: Motesanib 75
Normalized name: Motesanib
DrugBank: Motesanib (DB05575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motesanib 75 mg twice daily, 5-days-on/2-days-off (Arm C)
Study: 19180923
Drug: vecuronium bromide
Normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vecuronium bromide 0.1 mg/kg (control group)
Study: 16635694
Drug: Levalbuterol (Lev)
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levalbuterol (Lev) 1.25 mg
Study: 16635694
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (Rac) 2.5 mg
Study: 16635694
Drug: Racemic albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic albuterol (Rac)
Study: 8973725
Drug: anti-H2 treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-H2 treatment
Study: 19559376
Drug: Emergency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency treatment for renal colic
Study: 12088118
Drug: Droloxifene 40
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 40 mg/d
Study: 2127424
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion x 5 days recombinant gamma-interferon
Study: 31557693
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) + Treatment As Usual (TAU)
Study: 25573533
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1000 mg/m(2))
Study: 18046223
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) 1.25 mg and intravitreal triamcinolone (IVT) 2 mg
Study: 17550489
Drug: Menevit antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menevit antioxidant (one capsule per day for three months)
Study: 17550489
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical in appearance to Menevit, one capsule per day for three months)
Study: 24149401
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - no treatment
Study: 11598393
Drug: Oral folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral folate (5 mg/day)
Study: 9688014
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy at the time of symptomatic relapses
Study: 9688014
Drug: Fluconazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (up to 800 mg/day)
Study: 7805084
Drug: More potent
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More potent and specific antithrombin and antiplatelet agents
Study: 338851
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) and Spironolactone (SP) in combination